Breast Cancer
Conditions
Brief summary
Dexmedetomidine is widely used as an anaesthetic for general anesthesia during surgery. Previous studies in cells and animals show that dexmedetomidine may promote cancer growth. Using serum from breast cancer surgery patients randomized to receive dexmedetomidine or saline during surgery, we investigated the effects of dexmedetomidine on proliferation, migration and metastasis in MCF-7 breast cancer cells in vitro.
Detailed description
Women diagnosed with breast cancer undergoing elective surgery under general anesthesia will be randomly allocated to dexmedetomidine group or control group. Patients from both groups will receive midazolam, propofol, fentanyl, remifentanil and CIS atracurium for total intravenous anesthesia. BIS value will be controlled between 40-60 during surgery. Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery. Patients of control group will receive same amount of normal saline. Serum will be collected from patients of both groups at before induction and 1h post-surgery. The MCF-7 breast cancer cell line will be treated with patient serum from both groups. The effects of dexmedetomidine on cellular proliferation, migration and metastasis will be measured.
Interventions
DRUGDexmedetomidine
Patients in the experimental group will receive Dexmedetomidine during surgery.
DRUGsaline
Patients in the control group will receive saline but not Dexmedetomidine during surgery.
Sponsors
RenJi Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* ASA grade I-III Age range of 18 to75 Patients diagnosed primary breast cancer(T2-3, N0-2, M0) Patients will have elective adenomammectomy
Exclusion criteria
* with history of breast operation Patients diagnosed carcinoma erysipelatodes Severe liver, renal, brain or lung disease with history of opioid addiction Patients diagnosed metastatic breast cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cell proliferation | 24 hour post-surgery | MCF-7 cells will be cultured with serum from patients of both groups for 24 hours and cell proliferation will be measured |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cell migration | 24 hour post-surgery | MCF-7 cells will be cultured with serum from patients of both groups for 24 hours and cell migration will be measured |
| cell metastasis | 24 hour post-surgery | MCF-7 cells will be cultured with serum from patients of both groups for 24 hours and cell metastasis will be measured |
Countries
China
Outcome results
None listed